$STE

Zangerle John Adam sold $297K of STE

Zangerle John Adam (Sr. VP, Gen Counsel, and Sec.) sold 1,419 shares of STERIS plc (STE) at $209.28 ($0.30M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zangerle John Adam
Published Jun 16, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
high confidence
Mentioned
$STE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no other company-specific developments are provided.

02

Market read

This provides incremental transparency on insider activity but lacks fundamental catalysts, so trading impact is likely limited.

03

What to watch

Traders may overreact to insider sales; without changes in guidance, contracts, or litigation, the incremental information is mostly sentiment-level.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15.

Background

The article is a SEC Form 4 insider transaction disclosure for STERIS plc.

Company-level read

Ticker impact

$STENeutralHigh confidence
Context

STERIS disclosed an officer’s open-market sale of 1,419 shares at $209.28 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying fundamental or regulatory catalyst.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a pre-arranged 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • STERIS plc

    Subject of the Form 4 insider transaction disclosure.

  • Zangerle John Adam

    Sr. VP, General Counsel, and Secretary; reported an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

$STEHighAI 9/10

Steris Announces Major Acquisition of Xodus Medical, Inc.

STERIS (STE) agreed to acquire Xodus Medical, Inc. for $2.1B in cash, with up to $150M in earnout payments, subject to regulatory approval. The deal is expected to close by December 31, 2026, and will be financed primarily with debt. Analysts rate STE stock as Buy with a $269 price target, citing strong financial quality and growth guidance.

$STEHighAI 9/10

Steris inks $2.1B Xodus buyout to expand consumables portfolio

Steris (STE) agreed to acquire Xodus Medical for $2.1B, expecting $245M in annual sales. The deal expands Steris' healthcare consumables portfolio, with debt financing and potential performance-based payouts. Analysts expect earnings per share growth from 2027. Steris aims to close the deal this year, following its M&A strategy focused on hospital-related technology.

$STEHighAI 9/10

Steris outlays $2.1bn to acquire Xodus Medical

Steris (STE) agreed to acquire Xodus Medical, a privately held surgical safety solutions developer, for $2.1 billion. The deal will expand Steris's healthcare consumables portfolio, including Xodus's surgical products like the Pink Pad. Steris expects the acquisition to complement its offerings and drive growth, with Xodus projecting $245 million in 2026 revenue. Steris's healthcare consumables segment grew 10% year-on-year in Q2 2026.